Home › Non-Muscle Invasive Bladder Cancer › New York › New York City
Non-Muscle Invasive Bladder Cancer clinical trials in New York City, NY
10 studies for Non-Muscle Invasive Bladder Cancer are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
RecruitingPhase 2
- Icahn School of Medicine at Mount Sinai, New York
- Weill Cornell Medical Center, New York
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
RecruitingPhase 3
- Veterans Affairs New York Harbor Healthcare System-Manhattan Campus, New York
- Memorial Sloan Kettering Cancer Center, New York
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
RecruitingPhase 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0111), New York
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
RecruitingPhase 2
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center for Prostate and Urologic Cancers, New York
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center 53rd street, New York
- Icahn School of Medicine at Mount Sinai, New York
- and 3 more
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
RecruitingPhase 2
- Laura & Isaac Perlmutter Cancer Center - NYU Langone Health, New York
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RecruitingPhase 1
- New York University (NYU), New York
- Weill Cornell Medicine, New York
- Icahn School of Medicine at Mount Sinai, New York
- and 2 more
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
RecruitingPhase 3
- Columbia University (Data Collection Only), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Blue Light Cystoscopy With Cysview® Registry
RecruitingObservational study
- NYU Langone's Perlmutter Cancer Center, New York
Non-Muscle Invasive Bladder Cancer trials in other cities
- Columbus, OH10 studies
- Dallas, TX10 studies
- Myrtle Beach, SC9 studies
- Edison, NJ9 studies
- Baltimore, MD8 studies
- Nashville, TN8 studies
- Syracuse, NY8 studies
- Houston, TX7 studies
- Indianapolis, IN7 studies
- Philadelphia, PA7 studies
- Birmingham, AL7 studies
- Atlanta, GA7 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.